Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mir-19
- Development stage
- Phase 3
- Lead developer
- National Research Center - Institute of Immunology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
Mir-19 is an inhaled antiviral siRNA-based therapy developed by the Institute of Immunology of the Federal Medical-Biological Agency (FMBA) of Russia for the treatment of COVID-19. The drug consists of a specific small interfering RNA (siRNA) complexed with a peptide dendrimer (KK-46) that facilitates delivery into the lungs via a nebulizer. Mir-19 works by targeting a highly conserved sequence within the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) gene, triggering the RNA interference (RNAi) pathway to degrade the viral genome and inhibit replication. It was granted emergency use authorization in Russia in December 2021 and has been studied in clinical trials for both hospitalized patients with moderate disease and outpatients with mild COVID-19.
- Brand names
- Mir-19Mir19Mir 19
- Other names
- synthetic small interfering RNA
02
Targets
SARS-CoV-2 gRNA (SARS-CoV-2 genomic RNA)
Beyond the preview
Go deeper on Mir-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mir-19.